Biohaven Ltd. (BHVN) · Oct 29, 2026 · Earnings
Miss — Adjusted EPS $(0.73) vs ~$0.61 consensus
Biohaven’s third-quarter earnings missed the published EPS benchmark, while Ono and SK licensing deals materially strengthen funding for its clinical pipeline.
Biohaven is a clinical-stage biotech building MoDE and TRAP extracellular protein-degrader platforms, with BHV-1300 already in Phase 3 for Graves’ disease and BHV-1400 moving toward pivotal testing in IgA nephropathy. Its other major value driver, opakalim, remains in epilepsy development but is currently subject to a partial FDA hold on new enrollment.
The quarter itself missed the clean earnings benchmark. Adjusted loss per share was $0.73 versus a published consensus of roughly $0.61, while GAAP loss per share was $0.86. The year-over-year improvement came mainly from lower R&D spending after the company reprioritized programs, not from commercial revenue or a nearer-term product launch. The company reported adjusted net loss of $110.7 million versus $155.9 million a year earlier.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| GAAP net loss/share (Income Statement) | $(0.86) | $(1.64) | |
| Adjusted net loss/share (Non-GAAP reconciliation) | $(0.73) | $(1.47) | $(0.61) |
| R&D expense ($M) (R&D Expenses) | $101.9 | $141.2 | |
| Cash, cash equivalents, marketable securities and restricted cash ($M) (Liquidity) | $164.0 |
The bigger change is financial rather than quarterly. The Ono agreement has already delivered $80 million, with another $20 million milestone payment possible within roughly a year, while the SK Biopharmaceuticals deal is expected to provide $350 million at closing and another $50 million one year later. Together, those agreements represent up to $480 million of near-term cash consideration, although the SK proceeds remain dependent on closing.
The deals validate the platforms but also expose the remaining execution risk. Ono is taking regional rights to the MoDE IgG portfolio while Biohaven retains major territories, and SKBP is taking worldwide rights to the Kv7 platform. That gives Biohaven outside funding and development partners for two strategic assets, but the most valuable epilepsy program is not fully de-risked: the FDA has paused new opakalim enrollment while Biohaven completes additional nonclinical metabolite studies. 〔0〕
Regulatory optionality remains a meaningful near-term catalyst. The FDA accepted Biohaven’s Vyglxia resubmission for review, deemed it a complete response to the prior action letter, and assigned a user-fee goal date in the first quarter of 2027. That is new progress, but the planned advisory-committee review means approval is still a decision point rather than an achieved milestone. 〔1〕
Bottom line: This was an earnings miss, but the business story improved more than the quarter’s loss suggests because licensing proceeds can fund the pipeline without immediate equity dilution. The read is mixed because the central epilepsy asset still carries a regulatory hold and the largest SK payment has not yet closed.
RISE 3 topline data, 2H 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!